慢性病緩釋注射劑市場

Chronic Disease Markets for Sustained Release Injectables - Extended Coverage Version

出版日期: 2023年12月04日 | 出版商:

Greystone Research Associates | 英文 225 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

慢性病需要長期用藥，自我用藥變得越來越重要。隨著護理人員互動的轉變，用藥安全和依從性/依從性成為突出問題。這些擔憂並不新鮮，但隨著越來越多強大的新藥進入市場，這些擔憂也越來越嚴重。對於醫療保健管理者和公共衛生官員來說，解決這些問題的一種方法是減少給藥次數。使用旨在調節治療物質作用的製劑技術，藥物開發商正在開發具有緩釋特性的製劑。此類製劑技術包括聚乙二醇綴合物（聚乙二醇化）等聚合物，用於封裝和包覆新藥物。目標是透過控釋製劑滿足患者依賴性、依從性敏感的多劑量類藥物治療方案的要求，控釋製劑可以每天給藥一次或更少，以達到所需的治療效果。

本報告研究了全球慢性病緩釋注射劑市場，並提供了市場現狀、注射劑技術趨勢、需求驅動因素、競爭格局和未來預測。Masu。

自我管理的趨勢
注射配方技術
注射裝置設計的創新
推動治療需求的因素
市場因素
競爭狀況
風險因素
持續釋放 - 品牌配方技術
可生物降解聚合物
品牌SR混煉技術
物理過程控制方法
緩釋注射液 - 開發因素
組成元素
穩定性
凍乾
包裝
管理因素
SR 注塑 - 產品

市場領域分析與預測

成癮
納曲酮
糖尿病
艾塞那□
傳染病
幹擾素
荷爾蒙缺乏
雌二醇
生長激素
睪酮
代謝性疾病
肢端肥大症
神經病學
腫瘤學
白血病
淋巴瘤
阿糖胞甘
攝護腺
疼痛管理
生殖健康
生育能力
子宮內膜異位症

市場概況

簡介目錄

Product Code: SRK389F

“Chronic Disease Markets for Sustained Release Injectables: Technology, Therapeutics, Markets and Forecasts ” is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.

The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for injectable drug products engineered for controlled release. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

Engineered Injectables that Address Chronic Conditions

Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration. With the shift away from caregiver interaction, drug safety and compliance/adherence become prominent concerns. These concerns, which are not new, are becoming magnified as the number of powerful new drugs reaching the market increases. For healthcare managers and public health officials, one way to address these issues is less frequent dosing. Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended-release profiles. These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to product encapsulated and coated versions of new APIs. The goal is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with dosing of once-a-day or less.